地诺单抗纳入医保了没？

Is (Denosumab) included in medical insurance? Denosumab is a RANK ligand (RANKL) inhibitor with a different mechanism of action than currently approved drugs that reduce skeletal complications of tumors. It is a fully humanized monoclonal antibody (IgG2 monoclonal antibody) that specifically targets receptor activator of nuclear factor-κB ligand (RANKL). It prevents RANKL from binding to its receptor substances, inhibits osteoclast activation and development, reduces bone resorption, and increases bone density. On November 18, 2010, denosumab was approved to prevent bone-related events caused by cancer that has spread to the bone. On June 13, 2013, denosumab (denosumab) was approved to treat adults and adolescents with giant cell tumor of bone (GCTB), a rare and usually noncancerous tumor.

On October 26, 2018, Amgen Pharmaceuticals submitted a marketing application in China. Denosumab (Denosumab) was approved by the National Medical Products Administration in May 2019 for the treatment of giant cell tumor of bone that is unresectable or where surgical resection may cause severe functional disability, including adults and adolescent patients with skeletally mature disease (defined as at least 1 mature long bone and body weight >45 kg). The price of 120 mg of denosumab produced by Amgen in the United States is about $3,000. Therefore, the issue of medical insurance still needs to wait. If the patient needs to purchase denosumab (Denosumab), he or she can purchase it through the regular overseas medical service company Medical Companion Travel.

Precautions for Denosumab (Denosumab):

Hypocalcemia must be corrected before initiating treatment with denosumab. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D. Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to such patients. Physicians should evaluate the need to continue denosumab therapy in patients who develop serious infections while taking denosumab. Osteonecrosis of the jaw often occurs with tooth extraction and local infection that delays healing. A routine oral examination should be performed before starting treatment with (Denosumab), and good oral hygiene should be maintained after treatment is started. If a patient develops osteonecrosis of the jaw, treatment for osteonecrosis of the jaw may worsen the condition, and discontinuation of the medication should be considered at this time.

Recommended related hot articles: /newsDetail/74150.html